Hoth Therapeutics (NASDAQ:HOTH) Posts Earnings Results, Misses Expectations By $0.01 EPS

Hoth Therapeutics (NASDAQ:HOTH) posted its quarterly earnings data on Tuesday. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01), Zacks reports.

Hoth Therapeutics Stock Down 5.4 %

Shares of Hoth Therapeutics stock traded down $0.05 on Friday, hitting $0.80. The company’s stock had a trading volume of 140,828 shares, compared to its average volume of 1,389,183. The company has a market capitalization of $5.52 million, a P/E ratio of -0.59 and a beta of 0.84. Hoth Therapeutics has a 52-week low of $0.58 and a 52-week high of $1.73. The firm has a fifty day moving average price of $0.92 and a 200-day moving average price of $0.93.

Wall Street Analyst Weigh In

HOTH has been the topic of a number of recent analyst reports. EF Hutton Acquisition Co. I raised Hoth Therapeutics to a “strong-buy” rating in a report on Wednesday, August 21st. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Hoth Therapeutics in a research note on Monday, November 4th. Finally, Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 target price on shares of Hoth Therapeutics in a report on Friday, October 11th.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.